Ukr.Biochem.J. 2020; Volume 92, Issue 2, Mar-Apr, pp. 8-19


Hypertriglyceridemia is associated with long-term risk of cardiovascular events and specific comorbidity in very high-risk hypertensive patients

O. Ya. Korolyuk, O. M. Radchenko

Danylo Halytskyi Lviv National Medical University, Department of Internal Medicine No 2, Lviv, Ukraine;

Received: 19 December 2019; Accepted: 27 March 2020

Although hypertriglyceridemia (HTG) frequently occurs in hypertensive patients and may increase cardiovascular risk, the need for and manner of its reduction remain controversial. The objectives of this study were to compare lipid profiles, parameters of glucose homeostasis, comorbidity, and 5-year survival without cardiovascular events in very high-risk hypertensive (VHRH) patients with and without HTG, who received moderate intensity atorvastatin therapy. After initial assessment, 107 VHRH subjects were divided into two groups, i.e., without (n = 49) and with HTG (n = 58). During observation once annually patients were interviewed about prior hospitalizations with further screening for diabetes. Combined endpoint included­ hospitalization due acute myocardial infarction, decompensated heart failure, stroke or death. Survival was analyzed by Kaplan-Meier’s method. Nonparametric methods were used for statistical analysis. Higher median­ values of logarithmic value of triglycerides-to-HDL-cholesterol ratio, lipid accumulation product, fasting insulin, and HOMA index were observed in group 2 (< 0.002) that reflect predominance of small dense LDL particles, ectopic lipid deposition and insulin resistance. Patients with HTG more commonly had type 2 diabetes (58.6% vs 34.5%, including first-detected cases during initial assessments and observation, P = 0.02), liver steatosis (81.0% vs 55.1%, P = 0.006), and lithogenic gallbladder disorders (55.2% vs 34.7%, P=0.05). Women with HTG frequently had a history of hysterovariectomy (55.2% vs 19.0%, Р = 0.018). Despite long-term statin therapy, they often failed to reach recommended LDL-C targets and had worse survival due to significantly higher incidence of combined endpoint (39.6% vs 22.4%, P = 0.027). Further studies are necessary to find safe and effective strategy for secondary prevention in this population.

Keywords: , , , ,


  1.  Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J. 2020;41(1):111-188. PubMed, CrossRef
  2. Tune JD, Goodwill AG, Sassoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017; 183: 57-70. PubMed, PubMedCentral, CrossRef
  3. Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, Bouret S, Varma V, Hastings KL, Schug TT, Hart SGE, Burleson FG. Metabolic syndrome and associated diseases: from the bench to the clinic. Toxicol Sci. 2018; 162(1): 36-42. PubMed, PubMedCentral, CrossRef
  4. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018; 39(33):3021-3104. PubMed, CrossRef
  5. Chait A, Subramanian S. Hypertriglyceridemia: Pathophysiology, Role of Genetics, Consequences, and Treatment. [Updated 2019 Apr 23]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA):, Inc.; 2000. Available from:
  6. Dobiásová М, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem. 2001; 34(7): 583-588. PubMed, CrossRef
  7. Nascimento-Ferreira MV, Rendo-Urteaga T, Vilanova-Campelo RC, Carvalho HB, da Paz Oliveira G, Landim MBP, Torres-Leal FL. The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults. Clin Nutr. 2017; 36(6): 1693-1700. PubMed, CrossRef
  8. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006; 55(5): 1430-1435. PubMed, CrossRef
  9.  Gerst F, Wagner R, Oquendo MB, Siegel-Axel D, Fritsche A, Heni M, Staiger H, Häring HU, Ullrich S. What role do fat cells play in pancreatic tissue? Mol Metab. 2019;25:1-10. PubMed, PubMedCentral, CrossRef
  10.  Lee J, Lee YA, Kim JH, Lee SY, Shin CH, Yang SW. Discrepancies between glycosylated hemoglobin and fasting plasma glucose for diagnosing impaired fasting glucose and diabetes mellitus in Korean youth and young adults. Diabetes Metab J. 2019; 43(2): 174-182. PubMed, PubMedCentral, CrossRef
  11.  Smelt AHM. Triglycerides and gallstone formation. Clin Chim Acta. 2010; 411(21-22): 1625-1631. PubMed, CrossRef
  12.  Jonkers IJ, Smelt AHM, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CHBW, Masclee AAM. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut. 2003; 52(1): 109-115. PubMed, PubMedCentral, CrossRef
  13.  Kan HP, Guo WB, Tan YF, Zhou J, Liu CD, Huang YQ. Statin use and risk of gallstone disease: A meta-analysis. Hepatol Res. 2015; 45(9): 942-948. PubMed, CrossRef
  14. Pose E, Trebicka J, Mookerjee RP, Angeli P, Ginès P. Statins: Old drugs as new therapy for liver diseases? J Hepatol. 2019; 70(1): 194-202. PubMed, CrossRef
  15.  Li PC, Tsai IJ, Hsu CY, Wang JH, Lin SZ, Ding DC, Sung FC. Risk of Hyperlipidemia in women with hysterectomy – a retrospective cohort study in Taiwan. Sci Rep. 2018; 8(1): 12956. PubMed, PubMedCentral, CrossRef
  16. Newman CB, Preiss D, Tobert JA, Jacobson TA, RL Page II, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; on behalf of the American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientifc Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019; 39(2):e38-e81. PubMed, CrossRef
  17.  Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, Mundl H, Olsson AG. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
    J Am Coll Cardiol. 2015;65(21):2267-2275. PubMed, CrossRef
  18. Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants. J Am Heart Assoc. 2019; 8(19):e013543. PubMed, PubMedCentral, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.